

	Type	Hits	Search Text	DBs
1	BRS	241933	(UV OR ULTRAVIOLET)	USPAT; EPO; JPO; Derwent
2	BRS	7874	glutathione	USPAT; EPO; JPO; Derwent
3	BRS	19	((GLUTATHIONE) NEAR10 ((UV OR ULTRAVIOLET)))	USPAT; EPO; JPO; Derwent
4	BRS	1775	((424/60.CCLS.) OR (424/59.CCLS.))	USPAT; EPO; JPO; Derwent
5	BRS	7874	glutathione	USPAT; EPO; JPO; Derwent
6	BRS	111	(((((424/60.CCLS.) OR (424/59.CCLS.))) AND (GLUTATHIONE)))	USPAT; EPO; JPO; Derwent
7	BRS	1566	424/59.ccls.	USPAT; EPO; JPO; Derwent
8	BRS	2286	2.ti,ab.	USPAT; EPO; JPO; Derwent
9	BRS	3	(((((424/59.CCLS.) AND (GLUTATHIONE))) AND (2.TI,AB.)))	USPAT; EPO; JPO; Derwent
10	BRS	110	((424/59.CCLS.) AND (GLUTATHIONE))	USPAT; EPO; JPO; Derwent
11	BRS	1	"3821370".PN.	USPAT
12	BRS	66317	(ANTINFLAMMATORY OR ANTIINFLAMMATORY OR ANTI-INFLAMMATORY OR INFLAMMATION)	USPAT; EPO; JPO; Derwent
13	IS&R	2	("4847069").PN.	USPAT; EPO; JPO; Derwent
14	BRS	1566	424/59.ccls.	USPAT; EPO; JPO; Derwent
15	BRS	2286	glutathione.ti,ab.	USPAT; EPO; JPO; Derwent
16	BRS	3	((424/59.CCLS.) AND (GLUTATHIONE.TI,AB.))	USPAT; EPO; JPO; Derwent
17	BRS	15	(((((("5023235".PN.) OR ("4952391".PN.)) OR ("4847069".PN.)) OR ("4847071".PN.)) OR ("5216116".PN.)) OR ("4954332".PN.)))	USPAT; EPO; JPO; Derwent
18	IS&R	1566	("424/59").CCLS.	USPAT; EPO; JPO; Derwent
19	BRS	945	glutathione.ti.	USPAT; EPO; JPO; Derwent
20	BRS	241933	(UV OR ULTRAVIOLET)	USPAT; EPO; JPO; Derwent

	Time Stamp	Comments	Error Definition	Errors
1	2000/04/03 15:05			0
2	2000/10/06 14:40			0
3	2000/03/31 16:43			0
4	2000/10/10 14:46			0
5	2000/04/03 09:09			0
6	2000/04/03 09:10			0
7	2000/04/03 15:37			0
8	2000/04/03 09:10			0
9	2000/04/03 13:12			0
10	2000/04/03 10:05			0
11	2000/04/03 09:52			0
12	2000/04/03 09:56			0
13	2000/04/03 09:58			0
14	2000/04/03 13:13			0
15	2000/04/03 13:13			0
16	2000/04/03 13:14			0
17	2000/04/03 13:50			0
18	2000/04/03 13:51			0
19	2000/04/03 15:00			0
20	2000/04/03 15:06			0

	Type	Hits	Search Text	DBs
21	BRS	42	((GLUTATHIONE.TI.) AND ((UV OR ULTRAVIOLET)))	USPAT; EPO; JPO; Derwent
22	BRS	1566	424/59.ccls.	USPAT; EPO; JPO; Derwent
23	BRS	1	((530/331.CCLS.) AND (424/59.CCLS.))	USPAT; EPO; JPO; Derwent
24	BRS	3	"5023235".PN.	USPAT; EPO; JPO; Derwent
25	BRS	1094	530/331.ccls.	USPAT; EPO; JPO; Derwent
26	IS&R	1101	("514/18").CCLS.	USPAT; EPO; JPO; Derwent
27	IS&R	1037	("514/18").CCLS.	USPAT
28	BRS	8626	glutathione	USPAT; EPO; JPO; Derwent
29	BRS	1902	suntan or (sun adj tan)	USPAT; EPO; JPO; Derwent
30	BRS	5	(suntan or (sun adj tan)) near10 glutathione	USPAT; EPO; JPO; Derwent
31	BRS	252970	uv or ultraviolet	USPAT; EPO; JPO; Derwent
32	BRS	20	(uv or ultraviolet) near10 glutathione	USPAT; EPO; JPO; Derwent
33	IS&R	1640	("424/59").CCLS.	USPAT
34	BRS	1723	424/59.ccls.	USPAT; EPO; JPO; Derwent
35	BRS	116	424/59.ccls. and glutathione	USPAT; EPO; JPO; Derwent
36	IS&R	3	("4879370").PN.	USPAT; EPO; JPO; Derwent
37	BRS	1961	((424/60.CCLS.) OR (424/59.CCLS.))	USPAT; EPO; JPO; Derwent
38	BRS	1102	514/18.ccls.	USPAT; EPO; JPO; Derwent
39	BRS	1	514/18.ccls. and (((424/60.CCLS.) OR (424/59.CCLS.)))	USPAT; EPO; JPO; Derwent
40	BRS	3	4954332.pn.	USPAT; EPO; JPO; Derwent

	Time Stamp	Comments	Error Definition	Errors
21	2000/04/03 15:06			0
22	2000/04/03 15:37			0
23	2000/04/03 15:38			0
24	2000/04/03 15:38			0
25	2000/04/03 15:40			0
26	2000/10/10 14:47			0
27	2000/10/06 14:54			0
28	2000/10/06 14:41			0
29	2000/10/06 14:42			0
30	2000/10/06 14:44			0
31	2000/10/06 14:45			0
32	2000/10/06 14:45			0
33	2000/10/06 14:55			0
34	2000/10/06 14:56			0
35	2000/10/06 16:26			0
36	2000/10/06 16:26			0
37	2000/10/10 14:48			0
38	2000/10/10 14:47			0
39	2000/10/10 14:48			0
40	2000/10/10 15:02			0

(FILE 'HOME' ENTERED AT 10:01:16 ON 11 OCT 2000)

FILE 'REGISTRY' ENTERED AT 10:01:21 ON 11 OCT 2000

L1 1 S GLUTATHIONE/CN
 SEL L1

FILE 'CA, BIOSIS' ENTERED AT 10:01:50 ON 11 OCT 2000

L2 107433 S E1-E20
L3 446654 S UV OR ULTRAVIOLET OR ULTRA VIOLET
L4 1720 S L3 AND L2
L5 1893825 S IMMUN?
L6 112 S L5 AND L4
L7 41418 S SUN OR SUNTAN
L8 2 S L7 AND L6
L9 82 DUP REM L6 (30 DUPLICATES REMOVED)

L9 ANSWER 28 OF 82 CA COPYRIGHT 2000 ACS DUPLICATE 9
ACCESSION NUMBER: 129:287376 CA
TITLE: **Glutathione** ethylester protects against
local and systemic suppression of contact
hypersensitivity induced by **ultraviolet B**
radiation in mice
AUTHOR(S): Steenvoorden, David P. T.; Van Henegouwen, Gerard M.
J. Beijersbergen
CORPORATE SOURCE: Department of Medicinal Photochemistry,
Leiden/Amsterdam Center for Drug Research, University
of Leiden, Leiden, 2300 RA, Neth.
SOURCE: Radiat. Res. (1998), 150(3), 292-297
CODEN: RAREAE; ISSN: 0033-7587
PUBLISHER: Radiation Research Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Irradn. of the skin with **UV B** (UVB) radiation causes a local and
systemic suppression of T-cell-mediated **immune** responses.
Recently, N-acetylcysteine was found to protect against
UVB-radiation-induced **immunosuppression** and several other types
of damage induced by **UV** radiation. The protective effects
appeared to be caused by an increase in **glutathione** (**GSH**
) . This increase was limited by feedback inhibition by **GSH** of
its own synthesis. Better results were expected with the use of
GSH derivs. which do not require de novo synthesis, such as
GSH esters. In this study, topical application of
glutathione ethylester (**GSH-Et**) was found to increase
the epidermal **GSH** level in mice in a manner that was dependent
on dose to 1234% of the control value at the highest dose tested (2.0
.mu.mol/cm2). This resulted in dose-dependent protection against
UVB-radiation-induced suppression of contact hypersensitivity. The
highest dose of **GSH-Et** tested provided 83% protection against
local suppression and 62% protection against systemic suppression.
Immunosuppression induced by topically applied cis-urocanic acid
(cis-UCA) was prevented completely. Although an effect on the formation
of pyrimidine dimers cannot be excluded, the protective effect of
GSH-Et seems to be mediated through inhibition of the action of
cis-UCA.

L9 ANSWER 25 OF 82 CA COPYRIGHT 2000 ACS
 ACCESSION NUMBER: 129:250209 CA
 TITLE: **Immunopotentiators**
 INVENTOR(S): Yagi, Eiichiro; Naganuma, Masako; Iwai, Ichiro;
 Hatao,
 Masato; Yamaguchi, Kenji; Wada, Genji
 PATENT ASSIGNEE(S): Shiseido Company, Ltd., Japan
 SOURCE: PCT Int. Appl., 82 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9842363	A1	19981001	WO 1998-JP1094	19980316
W: AU, CN, KR, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9863116	A1	19981020	AU 1998-63116	19980316
EP 923938	A1	19990623	EP 1998-907241	19980316
R: DE, ES, FR, GB, IT, NL				
CN 1220607	A	19990623	CN 1998-800325	19980316
JP 11049696	A2	19990223	JP 1998-92471	19980320
JP 11071291	A2	19990316	JP 1998-92473	19980320
JP 11071295	A2	19990316	JP 1998-92472	19980320
JP 11106346	A2	19990420	JP 1998-92474	19980320
JP 11106348	A2	19990420	JP 1998-92475	19980320
JP 11106347	A2	19990420	JP 1998-92476	19980320
PRIORITY APPLN. INFO.:				
			JP 1997-87660	19970321
			JP 1997-163275	19970605
			JP 1997-185884	19970626
			JP 1997-185885	19970626
			JP 1997-224240	19970806
			JP 1997-225642	19970807
			JP 1997-225643	19970807
			WO 1998-JP1094	19980316

AB The invention relates to **immunopotentiators** contg. **glutathione** or a scutellaria root ext. for preventing skin **immune** depression caused by **UV** light or drugs for ameliorating or preventing skin **immune** depression caused by **UV** light; and **immunopotentiators** or drugs contg. an ext. of Tiliaceae, cloves, Geranium thunbergii or rosemary for ameliorating or preventing **immune** depression. These drugs can prevent skin **immune** depression caused by **UV** light.

L9 ANSWER 23 OF 82 CA COPYRIGHT 2000 ACS DUPLICATE 7
ACCESSION NUMBER: 130:193676 CA
TITLE: UVA-induced **immune** suppression through an
oxidative pathway
AUTHOR(S): Iwai, Ichiro; Hatao, Masato; Naganuma, Masako;
Kumano,
Yoshimaru; Ichihashi, Masamitsu
CORPORATE SOURCE: Shiseido Research Center, Yokohama, Japan
SOURCE: J. Invest. Dermatol. (1999), 112(1), 19-24
CODEN: JIDEAE; ISSN: 0022-202X
PUBLISHER: Blackwell Science, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Although UV B (UVB) irradiation induces local **immune** or systemic **immune** suppression, depending on the dose, the **immune** suppression by UV A (UVA) has not been fully investigated. In this study, we investigated the effect of UVA on the **immune** response in vitro and in vivo. The effect of UVA on the antigen-presenting function of epidermal cells was measured in terms of antigen-specific T cell proliferation. A murine epidermal cell suspension was exposed to UVA in vitro, pulsed with trinitrobenzenesulfonic acid, and cultured with T cells prepared from syngeneic mice previously sensitized with trinitrochlorobenzene. UVA (5-20 J per cm²) suppressed the antigen-presenting function of epidermal cells in a dose-dependent manner, accompanied with suppression of the expression of costimulatory molecules on Langerhans cells. In order to investigate the effect of an antioxidant on the **immune** suppression, an epidermal cell suspension was irradiated with UVA in the presence or absence of **glutathione**. The suppressions of antigen-presenting function and ICAM-1 expression were significantly prevented by **glutathione** in a dose-dependent manner. Further, the effect of UVA on the **immune** response at the induction phase of contact hypersensitivity was evaluated in terms of lymph node cell proliferation ex vivo. UVA irradiation suppressed the endogenous proliferation of lymph node cells in trinitrochlorobenzene-painted mice, and this suppression was significantly reversed by the application of **glutathione** to the skin during irradiation. These results suggest that UVA-induced **immune** suppression may be mediated by reactive oxygen species, at least in part.

REFERENCE COUNT: 48
REFERENCE(S): (2) Bannai, S; J Biol Chem 1979, V254, P3444 CA
(3) Beasley, D; Photochem Photobiol 1996, V64, P303
CA (4) Bestak, R; J Invest Dermatol 1995, V105, P345 CA
(5) Bestak, R; Photochem Photobiol 1996, V64, P969 CA
(6) Black, H; Photochem Photobiol 1987, V46, P213 CA
ALL CITATIONS AVAILABLE IN THE RE FORMAT



Creation date: 09-11-2003
Indexing Officer: TLAM2 - THY LAM
Team: OIPEBackFileIndexing
Dossier: 09147237

Legal Date: 03-28-2001

No.	Doccode	Number of pages
1	LET.	3

Total number of pages: 3

Remarks:

Order of re-scan issued on